Free tool
Drug Trial Radar: Dermatology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
14
Recruiting, industry sponsors, Dermatology, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed212
14 trials
Showing 1 to 14, recently updated first.
- A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07681271 · 100 participants (planned) · Start Jul 30, 2026 · Primary completion Dec 7, 2027
Drug: LOU064; Placebo · For: Papulopustular Rosacea
Sites: El Paso, Texas; Sofia, Bulgaria; London, Canada · 17 sites in all
- Safety of the Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe AcnePivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07756957 · 410 participants (planned) · Start Oct 14, 2026 · Primary completion Jul 19, 2028
Drug: Acne mRNA (messenger ribonucleic acid) vaccine; Placebo · For: Acne
Sites: Edmonton, Canada; Vancouver, Canada · 3 sites in all
Incyte CorporationIncyte (INCY)
NCT07213973 · 40 participants (planned) · Start Feb 2, 2026 · Primary completion Mar 25, 2028
Drug: Povorcitinib · For: Hidradenitis Suppurativa (HS)
Sites: Birmingham, Alabama; Phoenix, Arizona; Farmington, Connecticut · 28 sites in all
- Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or ObesityPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07830329 · 300 participants (planned) · Start Oct 29, 2026 · Primary completion Nov 24, 2028
Drug: Olatorepatide; Placebo · For: Hidradenitis Suppurativa
Sites: The Bronx, New York
Xinnate ABIndustry
NCT06594393 · 32 participants (planned) · Start Jan 30, 2026 · Primary completion Jun 30, 2027
Drug: TCP-25 gel; Vehicle (placebo) · For: Epidermolysis Bullosa (EB); Dystrophic Epidermolysis Bullosa; Junctional Epidermolysis Bullosa
Sites: Cincinnati, Ohio; Paris, France; Athens, Greece · 13 sites in all
Energenesis Biomedical Co., Ltd.Industry
NCT07858422 · 24 participants (planned) · Start Oct 8, 2026 · Primary completion Mar 15, 2027
Drug: ENERGI-F703EB Cream; Matched vehicle cream · For: Epidermolysis Bullosa (EB); Junctional Epidermolysis Bullosa; Epidermolysis Bullosa Simplex and 1 more
Sites: Tainan, Taiwan
- Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton SyndromePivotal-lookingRecruiting
Quoin PharmaceuticalsIndustry
NCT07538583 · 16 participants (planned) · Start Mar 19, 2026 · Primary completion Jan 31, 2027
Drug: QRX003 · For: Netherton Syndrome
Sites: Fremont, California; New Haven, Connecticut; Indianapolis, Indiana · 8 sites in all
- Clinical Study of QRX003 Lotion in Subjects With Netherton SyndromePivotal-lookingRecruiting
Quoin PharmaceuticalsIndustry
NCT06953466 · 8 participants (planned) · Start Oct 6, 2025 · Primary completion Dec 30, 2026
Drug: QRX003, 4% Lotion · For: Netherton Syndrome
Sites: Chicago, Illinois
- Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton SyndromePivotal-lookingRecruiting
Quoin PharmaceuticalsIndustry
NCT05789056 · 20 participants (planned) · Start Mar 14, 2023 · Primary completion Dec 30, 2026
Drug: QRX003, 4% Lotion · For: Netherton Syndrome
Sites: San Diego, California; Indianapolis, Indiana; Quincy, Massachusetts · 4 sites in all
- Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe AcnePivotal-lookingRecruiting
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT06316297 · 800 participants (planned) · Start Apr 5, 2024 · Primary completion Nov 30, 2028
Drug: Acne mRNA vaccine · For: Acne
Sites: Scottsdale, Arizona; Cerritos, California; Encino, California · 94 sites in all
BioMendics, LLCIndustry
NCT07027345 · 40 participants (planned) · Start Sep 11, 2025 · Primary completion Jan 2027
Drug: 5% TolaSure Topical Gel; Topical Placebo Gel · For: Epidermolysis Bullosa Simplex
Sites: Palo Alto, California; Chicago, Illinois
- Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild AcnePivotal-lookingRecruiting
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT07013747 · 228 participants (planned) · Start Jul 3, 2025 · Primary completion Jun 19, 2029
Drug: Acne mRNA vaccine · For: Acne
Sites: Encino, California; Brandon, Florida; Jacksonville, Florida · 4 sites in all
Aegle TherapeuticsIndustry
NCT04173650 · 8 participants (planned) · Start Aug 13, 2024 · Primary completion Sep 2025
Drug: AGLE-102 · For: Dystrophic Epidermolysis Bullosa
Sites: Phoenix, Arizona; Los Angeles, California; Philadelphia, Pennsylvania
- A Study of ATB1651 in Adults With Mild to Moderate OnchomycosisPivotal-lookingRecruiting
AmtixBio Co., Ltd.Industry
NCT06327295 · 120 participants (planned) · Start Jul 1, 2024 · Primary completion Jun 30, 2025
Drug: ATB1651-102- Cohort 1; ATB1651-102- Cohort 2 and 3 more · For: Onychomycosis
Sites: Christchurch, New Zealand
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.